secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0000950170-23-029413
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical shareholders re-elect all three director nominees
----------------------------------------------------------------------

- Jeffrey L. Edwards, Clay B. Thorp, and Benjamin R. Yerxa re-elected with 21.0M, 21.0M, and 22.8M votes for, respectively.
- Advisory vote on executive compensation passed with 21.9M for, 1.0M against, 2.3M abstain.
- Ratification of Ernst & Young as auditor for FY 2023 approved (40.2M for, 0.1M against).
- Turnout: 40.7M shares (65.98%) of 61.7M outstanding present or represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/0000950170-23-029413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/clsd-20230622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer